Boston Therapeutics
is developing a pipeline of novel compounds to address unmet medical needs in
diabetes. The company’s current product pipeline is focused on developing and
commercializing the therapeutic molecules PAZ320 for patients with diabetes;
and IPOXYNT for a wide rand of indications such as anemia and blood loss
(injury), cardiovascular disease, and surgical blood supplementation.
Boston Therapeutics’
technology platform in applied carbohydrate chemistry has been pioneered by
company CEO Dr. David Platt, who for the last 20 years has worked alongside
scientific collaborators to safely address medical needs for oral and
injectable applications.
Dr. Platt is
recognized worldwide as an expert in carbohydrate chemistry and has led two
drug candidates from concept to human clinical trials. He also founded three
publicly traded companies: Pro-Pharmaceuticals, Inc., SafeScience, Inc., and
International Gene Group. Dr. Platt’s guidance is supported by an executive
management team with more than 100 years of combined experience.
Providing additional
expertise, Boston Therapeutics has established a scientific advisory team with
extensive expertise in complex carbohydrate chemistry, regulatory, and clinical
development, with multiple submissions and approvals to U.S. Food and Drug
Administration.
Under this
leadership, Boston Therapeutics anticipates initiating a pivotal phase 3 study
of PAZ320. The two-year study, to be conducted in the U.S., Europe, Hong Kong,
Korea, and China, will be evaluate the effects of the drug candidate on glucose
and hemoglobin A1c (HbA1c) in approximately 300 Type 2 patients currently
taking metformin.
In an earlier phase
2 study, PAZ320 achieved a 40 percent reduction in post-meal blood glucose
levels with no serious adverse events.
For additional
information, visit www.BostonTI.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment